Drug Approval | June 05, 2025
UK MHRA approves aumolertinib to treat non-small cell lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
The initiative was announced at World Hypertension Congress, Chennai
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
